Anktiva (nogapendekin alfa inbakicept-pmln)

Adult Dosing .

Dosage forms:  SOLUTION

Special Note

[drug name clarification]

Info: nonproprietary name = nogapendekin alfa inbakicept-pmln

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing

non-muscle invasive bladder CA in situ, BCG-unresponsive

[induction tx]

Dose: 400 mcg intravesically qwk x6wk; Info: for patients with or without papillary tumors; use with BCG; may repeat induction tx x1 if complete response not achieved at month 3

[maintenance tx, patients in complete response after 1st induction tx]

Dose: 400 mcg intravesically qwk x3wk at months 4, 7, 10, 13, and 19; Info: for patients with or without papillary tumors; use with BCG; if continued complete response, may give additional 400 mcg intravesically qwk x3wk at months 25, 31, and 37 for max tx duration of 37mo

[maintenance tx, patients in complete response after 2nd induction tx]

Dose: 400 mcg intravesically qwk x3wk at months 7, 10, 13, and 19; Info: for patients with or without papillary tumors; use with BCG; if continued complete response, may give additional 400 mcg intravesically qwk x3wk at months 25, 31, and 37 for max tx duration of 37mo

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.